Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Aldevron
8 Articles Available
Can't find what you're looking for? Try our
advanced search
.
Plasmids
The Pivotal Role of Plasmid DNA
PAP-Q4-19-CL-006
Expansion
Aldevron Breaks Ground on 14-Acre Campus Expansion
PR-M08-19-NI-059
Gene Therapy
Expanding GMP Gene Therapy Manufacturing Capacity
PTV-M08-19-BIO-003
Gene Therapy
Accelerating Innovation for Gene Therapy
PTV-M08-19-BIO-002
M&A
EQT to Acquire Majority Interest in Aldevron – the Leading Global Supplier of Plasmid DNA Used in Cell and Gene Therapies
PR-M07-19-NI-081
Cell and Gene Therapy
Gene Editing Solutions with Off-the-Shelf GMP CRISPR/Cas9 Nucleases
PAO-06-2019-CL-002
Cell and Gene Therapy
Aldevron to Build 14-Acre Gene Therapy Manufacturing Campus
PR-M06-NI-002
AAV and LV Vectors
Supporting AAV and Lentiviral Vector Development and Commercialization
PAP-Q2-2019-CL-005
